Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologyPresbyterian Allergen Testing Coverage | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedPresbyterian Health PlanPolicy AHS - G2031

    Allergen Testing

    Customize your policy alerts

    Sign up for Presbyterian Health Plan Policy AHS - G2031 alerts

    Get alerted when Policy AHS - G2031 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of skin and in-vitro allergen testing, including specific and total serum IgE testing and selected proprietary or emerging assays. Coverage applies according to the member’s benefit plan and the clinical indications and limitations described in the policy.

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyAllergen Testing
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateOct 15, 2026
    Next Review DateN/A
    Key ActionSelect allergens based on the patient's history, physical examination, age, environment, geographic region, occupation, and activities.
    SourceLink
    POLICY UPDATE CHANGES

    CPT code 95004 was added to the applicable procedure codes.

    The policy background, guidelines, recommendations, and evidence-based scientific references were updated effective October 15, 2026.

    A former clinical-guidance criterion addressing specific IgE testing situations and its associated skin-testing contraindication note were removed.

    The wording of CC3 was revised for clarity and consistency to support enforcement.

    Former CC7 and CC8 were combined into one criterion stating that basophil activation flow cytometry and in-vitro IgG, IgA, IgM, and IgD testing do not meet coverage criteria for individuals with allergy signs or symptoms.

    Up to 20/yearCovered allergen-specific IgE antibodies when testing is guided by history, examination, and environment
    2 indicationsCovered total serum IgE indications
    AnnualCovered repeat testing interval for the same positive food allergens in children and adolescents
    5 categoriesExplicitly noncovered testing categories or circumstances
    95004CPT code added in the current revision

    Covered and Noncovered Allergen Testing

    Specific IgE in-vitro testing

    Covered when all of the following are met:

    Specific IgE in-vitro testing: Specific IgE in-vitro allergy testing is covered when the allergens are selected based on the individual's history, physical examination, and environment.up to 20 allergen-specific antibodies per year

    Testing beyond 20 allergen-specific antibodies per year does not meet coverage criteria.

    Total serum IgE

    Covered when any of the following are met:

    Total serum IgE indications

    • Moderate-to-severe asthma: The individual has moderate to severe asthma.
    Policy Summary
    PayerPresbyterian Health Plan
    PolicyAllergen Testing
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateOct 15, 2026
    Next Review DateN/A
    Key ActionSelect allergens based on the patient's history, physical examination, age, environment, geographic region, occupation, and activities.
    SourceLink
    On This Page
    Covered and Noncovered Allergen TestingApplicable Procedure Codes and LimitsDocumentation, Test Selection, and Denial RisksClinical BackgroundTerminology and Testing Modalities
    Possible allergic bronchopulmonary aspergillosis: The individual has signs or symptoms of allergic bronchopulmonary aspergillosis.

    Repeat food-allergen testing in children and adolescents

    Covered when all of the following are met:

    Monitoring food-allergy resolution

    • Age group: The individual is a child or adolescent.
    • Initial positive result: The individual has an initial positive food allergen result or results.
    • Same food allergen(s): Repeat testing is for the same food allergen(s).

    Clinical indications for skin prick testing

    Skin prick testing is indicated in selected patients with a clinically suspected allergic condition, including:

    Clinically suspected allergic conditions

    • Respiratory allergic disease: Asthma, rhinitis, rhinosinusitis, rhinoconjunctivitis, or conjunctivitis with suspected allergic sensitization.
    • Selected skin disease: Eczema or atopic dermatitis when there is selectively high clinical suspicion for IgE hypersensitivity to specific allergens.
    • Suspected food allergy, including oral allergy syndrome, anaphylaxis, or acute-onset or food-associated exacerbation of urticaria or eczema.
    • Suspected drug allergy.
    • Hymenoptera venom allergy: A systemic reaction occurring immediately after an insect sting.
    • Occupational exposure: Suspected occupational disease or exposure to selected potential allergens.
    • Selected chronic urticaria: Chronic urticaria in rare, selected cases in which the history strongly suggests an allergen as a trigger or aggravating factor.
    • Selected eosinophilic or allergic disorders: Less common disorders such as eosinophilic esophagitis, eosinophilic gastroenteritis, or allergic bronchopulmonary aspergillosis when IgE sensitization is part of the disease pathogenesis.

      The utility of SPT for these illnesses may be controversial.

    Situations where skin prick testing is not routinely indicated

    SPT is not routinely indicated when one or more of the following is present without other features of allergic disease:

    Routine non-indications

    • Suspected food intolerance, including irritable bowel syndrome.
    • Chronic urticaria without allergic features in the history.
    • Weight-loss evaluation: Desire to lose weight based on an unsupported food-intolerance explanation for obesity.
    • Non-specific food-associated symptoms: Non-specific symptoms attributed to food additives, preservatives, or colorants.
    • Immunotherapy effectiveness: Evaluation of the effectiveness of allergen immunotherapy, except that testing may be supportive during Hymenoptera venom immunotherapy.
    • Irritant respiratory symptoms: Non-specific respiratory symptoms attributed to smoke, perfumes, detergents, chemicals, or other strong odors.
    • Asymptomatic screening: Screening for allergic sensitization patterns in the absence of clinical symptoms, including testing based only on family history of allergy.
    • Non-specific rash: Non-specific cutaneous rashes without atopic features or other allergic symptoms.
    • Migraine, except when evaluating specific hypersensitivity to hormones.
    • Chronic fatigue syndrome.

    Patch testing for suspected allergic contact dermatitis

    Patch testing should be considered or performed when allergic contact dermatitis is suspected, particularly in the following presentations:

    Suspected allergic contact dermatitis presentations

    • Chronic or localized dermatitis: Chronic eczematous or noneczematous dermatitis, including generalized or localized eruptions involving the hands, face, or eyelids.
    • Hand dermatitis: Acute or chronic hand eczema or dermatitis, with evaluation for both irritant and allergic causes.
    • Cosmetic-related facial dermatitis: Facial or periorbital dermatitis in which cosmetics, fragrances, preservatives, or excipients may be causative sensitizers.
    • Product-associated dermatitis: Scalp, neck, axillary, anogenital, lip, or perioral dermatitis potentially related to cosmetics, hair products, deodorants, textiles, or topical products.
    • Systemic contact dermatitis: Generalized dermatitis, intertriginous or flexural exanthema, or flares at previous exposure sites after systemic exposure to a known contact sensitizer.
    • Footwear-associated dermatitis: Unexplained chronic dermatitis of the lower extremities, feet, or soles, with consideration of testing to rubber chemicals, adhesives, and leather components.

    Condition-specific allergen testing

    Testing should be selected according to the suspected condition and clinical probability:

    Condition-specific testing recommendations

    • Rhinitis or rhinosinusitis: Evaluate for aeroallergen-specific IgE using skin prick or serum-specific IgE testing to confirm allergic rhinitis when the history is compatible; do not routinely perform food skin prick or serum-specific IgE testing for rhinitis symptoms.

      Local allergic rhinitis may have negative skin and serum testing and a positive nasal allergen provocation test.

    • Suspected food allergy: Use focused skin prick and/or serum-specific IgE testing for foods suspected of causing the reaction; consider oral challenge when feasible and do not use test results alone as diagnostic proof.

      Routine total serum IgE testing is not recommended for diagnosing food allergy.

    • Suspected peanut allergy: Consider SPT or serum-specific IgE in patients with high pretest probability and before oral food challenge in patients with moderate pretest probability; Ara h 2 may be used as a single diagnostic test because of its diagnostic accuracy.

      Ara h 2 has lower sensitivity than SPT or whole-peanut serum-specific IgE. Routine component testing in addition to SPT or whole-peanut serum-specific IgE is not recommended, and these results should not be used to predict reaction severity.

    • Anaphylaxis: Use skin tests and/or in-vitro-specific IgE testing and challenge testing when appropriate to help identify the cause; for suspected perioperative anaphylaxis, test potential culprit and alternative agents when available.

      After perioperative anaphylaxis, delay testing unless surgery cannot be postponed; perform challenges to agents with negative testing when feasible.

    History-directed allergen testing

    All of the following clinical conditions should be considered when selecting allergen testing:

    History-directed testing

    • Potential indications: The patient has a condition in which IgE-mediated sensitization may be clinically relevant, such as asthma; rhinitis, rhinosinusitis, rhinoconjunctivitis, or conjunctivitis; selected atopic dermatitis; suspected food or drug allergy; systemic Hymenoptera venom reaction; suspected occupational allergy; selected chronic urticaria with a strongly suspected allergen trigger; or selected eosinophilic or allergic bronchopulmonary disorders.

      The utility of testing may be controversial for some less common disorders.

    • Appropriate test selection: Use skin-prick testing or serum-specific IgE according to the clinical situation, test safety, patient acceptability, and provider competency.

      Serum-specific IgE is an alternative when SPT cannot be performed.

    Peanut allergy prevention testing

    For infants being considered for peanut introduction:

    Peanut evaluation before introduction: Strongly consider peanut-specific IgE measurement, skin-prick testing, or both before introducing peanut to determine whether and how peanut should be introduced.

    Peanut-specific IgE may be the preferred initial approach where SPT is not routine.

    Higher-risk infants: For an infant with severe eczema, egg allergy, or both, strongly consider evaluation with peanut-specific IgE measurement and/or SPT and, if necessary, an oral food challenge before introducing peanut-containing foods.

    Do not add broad food-panel testing solely because peanut testing is being considered.

    Allergic rhinitis testing

    For suspected allergic rhinitis:

    Allergic-rhinitis evaluation: Use history and physical examination as the foundation of diagnosis; use diagnostic skin testing or serum-specific IgE when confirmation is needed for allergen immunotherapy, targeted avoidance, or inadequate treatment response.

    Nasal-specific IgE, component-resolved diagnostics, nasal provocation, or basophil activation testing may be considered only in selected specialist circumstances. FeNO or nasal nitric oxide testing should not be routinely used for diagnosis.

    Testing not routinely indicated

    Testing is generally not indicated when allergic disease is not supported by the clinical history:

    Low-yield clinical scenarios: The presentation consists of suspected food intolerance, chronic urticaria without allergic features, weight-loss evaluation, nonspecific symptoms attributed to food additives or preservatives, evaluation of immunotherapy effectiveness, nonspecific irritant-related respiratory symptoms, screening without clinical symptoms, nonspecific rash without atopic features, migraine without a specific hypersensitivity indication, or chronic fatigue syndrome.

    These scenarios are listed as not routinely indicated in the absence of other features of allergic disease. Allergen-specific IgE testing is also not indicated for isolated, randomly occurring urticaria or urticaria without a clear and consistent exposure-related trigger.

    Routine re-testing for the same allergens does not meet coverage criteria when there is no new clinical presentation. The exception is annual re-testing of the same positive food allergen(s) in children and adolescents to monitor allergy resolution.

    The antigen leukocyte antibody test (ALCAT) does not meet coverage criteria.

    For individuals with allergy signs or symptoms, basophil activation flow cytometry and in-vitro testing of IgG, IgA, IgM, or IgD do not meet coverage criteria.

    In-vitro allergen testing using bead-based epitope assays, including assays such as VeriMAP Peanut Dx, does not meet coverage criteria.

    Qualitative specific IgE multi-allergen screening that does not identify a specific allergen does not meet coverage criteria in any situation.

    IgG and IgG-subclass testing for food allergy should not be performed because it lacks clinical relevance, validation, and sufficient quality control. These tests are not supported for diagnosing food allergy.

    Routine component testing in addition to skin-prick testing or whole-peanut specific IgE is not recommended. Skin-prick or specific IgE results should not be used to predict the severity of a future allergic reaction.

    Food skin-prick testing or serum-specific IgE testing should not be performed routinely for patients presenting with signs or symptoms compatible with rhinitis. Evaluation should instead focus on suspected aeroallergens when the clinical history supports allergic rhinitis.

    Specific IgG testing for food panels and allergen-specific IgG testing should not be used to diagnose food allergy or other allergic disease. Clinically indicated serum-specific IgE or skin-prick testing should be selected based on the patient's history.

    Nonstandardized tests, including basophil histamine-release or activation, lymphocyte-stimulation, cytotoxicity, and mediator-release assays, should not be used in the routine evaluation of food allergy.

    Food allergen panel testing, or adding specific IgE testing for foods other than peanut, is not recommended solely for peanut introduction assessment because of poor positive predictive value and the risk of overdiagnosis and unnecessary dietary restrictions.

    Atopy patch testing and oral food challenges should not be used to diagnose IgE-mediated food allergy in primary-care or community settings.

    Routine multiplex allergen testing with ImmunoCAP ISAC is not supported by sufficient evidence for diagnosing allergy or predicting the risk of an allergic reaction.

    FeNO or nasal nitric oxide testing should not be routinely used as the diagnostic evaluation for allergic rhinitis. History and physical examination, diagnostic skin testing, or serum-specific IgE testing are first-line approaches.

    The excluded testing categories do not meet coverage criteria because published scientific literature is insufficient to confirm that the tests are required and beneficial for diagnosing and treating the individual's illness.

    Allergen testing is not routinely indicated for nonspecific food intolerance, chronic urticaria without allergic features, nonspecific irritant-related symptoms, nonspecific rash without atopic features, asymptomatic screening, or isolated urticaria without a clear and consistent exposure-related trigger.

    Broad, indiscriminate allergen panels without a history-specific clinical indication are not medically useful. Positive results may represent sensitization rather than clinical allergy and can lead to false-positive interpretations, overdiagnosis, and unnecessary dietary restrictions.

    Routine total serum IgE alone is not appropriate for diagnosing food allergy. Serum-specific IgE or skin-prick results alone also do not establish a food-allergy diagnosis; results must be interpreted with the clinical history.

    Routine multiplex allergen testing lacks sufficient evidence for adoption in difficult-to-diagnose allergy when used with standard clinical assessment.

    Applicable Procedure Codes and Limits

    Applicable CPT/HCPCS Procedure CodesCPT
    82784Gammaglobulin (immunoglobulin); IgA, IgD, IgG, IgM, each
    82785Gammaglobulin (immunoglobulin); IgE
    82787Gammaglobulin (immunoglobulin); immunoglobulin subclasses (eg, IgG1, 2, 3, or 4), each
    83516Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method
    86001Allergen specific IgG quantitative or semiquantitative, each allergen
    86003Allergen specific IgE; quantitative or semiquantitative, crude allergen extract, each
    86005Allergen specific IgE; qualitative, multiallergen screen (eg, disk, sponge, card)
    88184Flow cytometry, cell surface, cytoplasmic, or nuclear marker, technical component only; first marker
    95004Percutaneous tests (scratch, puncture, prick) with allergenic extracts, immediate type reaction, including test interpretation and report, specify number of tests
    Applicable Proprietary Laboratory Procedure CodesHCPCS
    0165UPeanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA), blood, individual epitope results and probability of peanut allergy. Proprietary test: VeriMAP Peanut Dx - Bead-based Epitope Assay; Lab/Manufacturer: AllerGenis Clinical Laboratory
    0178UPeanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA), blood, report of minimum eliciting exposure for a clinical reaction. Proprietary test: VeriMAP Peanut Sensitivity - Bead Based Epitope Assay; Lab/Manufacturer: AllerGenis Clinical Laboratory
    Specific IgE testing limit
    LimitUp to 20 allergen-specific antibodies per year
    Selection basisAllergens must be selected according to the individual's history, physical examination, and environment.
    Coverage contextSpecific IgE in-vitro allergy testing meets coverage criteria when the testing is limited to appropriately selected allergens.
    Repeat food-allergen testing interval
    IntervalAnnual re-testing
    PopulationChildren and adolescents with an initial positive food allergen result or results
    Testing scopeRepeat testing must be for the same food allergen(s) and used to monitor allergy resolution.

    Documentation, Test Selection, and Denial Risks

    Documentation Required

    Base Test Selection on the Clinical Record

    Select specific IgE testing only when the clinical record supports the allergens chosen through the individual's history, physical examination, and environment. Coverage is limited to up to 20 allergen-specific antibodies per year when this directed-selection requirement is met.

    Documentation Required

    Use History and Exposure to Target Allergens

    Choose allergens for skin testing or in-vitro specific IgE testing based on the patient's history, examination, age, environment and living conditions, geographic region, occupation, and activities. Select relevant regional allergens and consider the clinical setting when choosing between skin testing and serum testing.

    • Use the patient's exposure pattern and symptoms to identify likely causal allergens.
    • For pollens, consider regional prevalence and symptoms during recurrent seasons.
    • Serum testing may be preferable when skin disease, suppressive medications, lack of cooperation, or an elevated risk of anaphylaxis makes skin testing unsuitable.
    Documentation Required

    Interpret Food Allergy Tests in Clinical Context

    For suspected food allergy, direct skin-prick or serum-specific IgE testing to foods suspected of provoking the reaction. Test results demonstrate sensitization and must not be considered diagnostic of food allergy in isolation; interpret them with the exposure history, signs, and symptoms.

    • Base suspected food-induced anaphylaxis on compatible signs and symptoms associated with likely or known food exposure.
    • Do not use skin-prick or specific IgE results alone to determine the severity of an allergy phenotype or predict the severity of a future reaction.
    Documentation Required

    Document an Allergy-Focused History

    Before ordering allergy testing, document an allergy-focused history and physical examination addressing the suspected exposure, timing, symptoms, and clinical pattern. For food allergy, assess whether symptoms are consistent with an IgE-mediated mechanism, occur within minutes to an hour, are attributable to a likely allergen, and recur with subsequent exposure.

    • Document the relevant exposure and whether symptoms occur without that exposure.
    • For inhalant allergy, order testing when the result will directly affect management or referral.
    • A prior tolerance history does not by itself exclude allergy.
    Documentation Required

    Document Clinical Interpretation

    Document the interpretation of each test in the context of the allergy-focused history, examination, and clinical findings, including how the result changes diagnosis or management. A positive specific IgE result indicates sensitization and does not by itself establish clinical allergy.

    • Explain the diagnostic and treatment impact of the result.
    • Consider whether the result correlates with the patient's symptoms and likely exposure.
    Documentation Required

    Use Qualified Personnel and Safe Facilities

    Skin-prick testing must be performed and interpreted by healthcare professionals with appropriate training and competency. Perform skin-prick testing only in facilities equipped to recognize and manage anaphylactic reactions.

    • The clinician interpreting results should have adequate knowledge of the medical history, clinical findings, and relevant environmental, food, insect, fungal, animal, and drug allergens.
    • Choose skin testing versus serum-specific IgE based on safety, suitability, acceptability, and available clinician competency.
    Documentation Required

    Document the Basis for Food Allergy Testing

    For food allergy, document that testing is consistent with a suspected IgE-mediated reaction and record the timing, reproducibility, likely trigger, and relationship of symptoms to exposure. Limit allergen-specific IgE testing to the relevant trigger food and clinically indicated coallergens.

    • Record whether symptoms are compatible with an IgE-mediated mechanism.
    • Record whether symptoms occur within minutes to an hour and recur with subsequent exposure.
    • Do not test foods that are clinically tolerated merely because they are included in a panel.
    Denial Risk

    Avoid Unfocused Specific IgE Testing

    Unfocused or excessive specific IgE testing is not covered when the allergens are not directed by the patient's history, physical examination, or environment. Test selection must identify clinically relevant suspected allergens rather than screen indiscriminately.

    • Specific IgE coverage is limited to up to 20 allergen-specific antibodies per year when selection is clinically directed.
    Denial Risk

    Repeat Testing Requires a New Presentation

    Routine repeat testing for the same allergens is not covered when there is no new clinical presentation. The specified exception is annual retesting of the same food allergen or allergens to monitor resolution in children and adolescents with an initially positive food-allergen result.

    • Document the new presentation when repeat testing is requested.
    • For the exception, document the child's or adolescent's initial positive food-allergen result and the purpose of annual monitoring.
    Denial Risk

    ALCAT Testing Not Covered

    ALCAT (antigen leukocyte antibody test) testing does not meet coverage criteria and is not covered.

    Denial Risk

    Unsupported Antibody and Basophil Testing Not Covered

    Basophil activation flow cytometry and in-vitro testing for IgG, IgA, IgM, or IgD do not meet coverage criteria for allergy evaluation because published evidence does not establish that these tests are required and beneficial for diagnosis or treatment.

    • Basophil histamine or leukotriene release assays may be research tools but are not routine covered diagnostic testing.
    • IgG and IgG-subclass food testing lacks clinical relevance, validation, and sufficient quality control.
    Denial Risk

    Bead-Based Epitope Assays Not Covered

    In-vitro allergen testing using bead-based epitope assays is not covered, including proprietary VeriMAP Peanut Dx and VeriMAP Peanut Sensitivity assays.

    • Referenced procedure codes include 0165U and 0178U.
    • Do not substitute bead-based epitope assays for clinically directed skin-prick or serum-specific IgE testing.
    Denial Risk

    Nonspecific Multi-Allergen Screens Not Covered

    Qualitative specific IgE multi-allergen screening that does not identify a specific allergen does not meet coverage criteria. Order testing that identifies clinically suspected allergens and can be interpreted against the patient's history.

    Denial Risk

    Avoid Unproven or Indiscriminate Testing

    Do not order unproven or indiscriminate testing, including IgG or IgG-subclass food panels, unproven diagnostic methods, or indiscriminate batteries of IgE tests. Such testing can produce misleading results, overdiagnosis, unnecessary dietary restrictions, and inappropriate treatment.

    • Specific IgG indicates prior exposure rather than hypersensitivity.
    • Nonstandardized tests such as cytotoxicity, lymphocyte-stimulation, and mediator-release assays should not be used routinely for food allergy.
    Denial Risk

    Require a Clinically Directed Indication

    Do not perform routine allergy testing without a clinically directed indication. Testing is not supported for nonspecific presentations such as chronic urticaria without a clear allergic trigger, routine food testing in rhinitis evaluation, nonspecific food-associated symptoms, or screening in asymptomatic individuals.

    • Do not routinely perform food skin-prick or specific IgE testing for signs and symptoms compatible with allergic rhinitis.
    • Do not use allergy testing for nonspecific rashes, irritant-related respiratory symptoms, weight-loss approaches, migraine, or chronic fatigue without a supported clinical indication.
    Denial Risk

    Use Standardized Food Allergy Methods

    Do not substitute specific IgG panels or other nonstandardized methods for indicated serum-specific IgE or skin-prick testing. The selected method must be validated and appropriate to the suspected allergic condition.

    • Specific IgG to food panels is not a validated measure of hypersensitivity.
    • Routine food-allergy evaluation should use clinically directed skin-prick and/or serum-specific IgE testing when indicated.
    Denial Risk

    Avoid Indiscriminate Allergy Panels

    Do not order indiscriminate skin or serum IgE panels without history specific to the suspected allergen. Broad panels increase false-positive findings, which can lead to incorrect diagnoses, unnecessary dietary restrictions, and inappropriate care.

    • For peanut evaluation, do not add foods other than peanut through panel testing when not clinically indicated.
    • Base testing and treatment decisions on history and directed testing; positive results indicate sensitization, not necessarily clinical allergy.
    Denial Risk

    Avoid Unsupported Routine Food-Allergy Tests

    Atopy patch testing, routine total serum IgE for food allergy, and routine combinations of skin-prick testing, specific IgE, and atopy patch testing are not supported for routine food-allergy diagnosis. Total IgE may have limited clinical value in other covered circumstances, such as moderate to severe asthma or suspected allergic bronchopulmonary aspergillosis.

    • Do not use routine total serum IgE to diagnose food allergy.
    • Do not combine SPT, serum-specific IgE, and atopy patch testing routinely for food allergy.
    Denial Risk

    Do Not Routinely Use Adjunctive Tests

    FeNO and nasal nitric oxide testing should not be routinely used as first-line evaluation for allergic rhinitis because evidence is inconsistent and no agreed diagnostic cutoff exists. Use history and physical examination with directed skin testing or serum-specific IgE first; consider nitric oxide testing only as an additional evaluation when necessary.

    • Other unsupported adjunctive tests should not replace clinically directed allergy testing.
    • Serum total or specific IgE should not be used to diagnose asthma; directed testing may identify triggers after asthma is formally diagnosed.
    Denial Risk

    Urticaria Requires a Clear Allergic Trigger

    Allergen-specific IgE testing is not indicated for isolated or randomly occurring urticaria, with or without angioedema, when there is no clear and consistent exposure history. Most such urticaria is spontaneous rather than caused by allergy.

    • Order testing only when the history identifies a clear allergen as a provoking or perpetuating factor.
    • Document the exposure relationship and reproducibility if testing is requested.

    Clinical Background

    Allergic disease includes type I immediate IgE-mediated reactions and type IV T-cell-mediated reactions. Serum-specific IgE or skin testing may assess IgE-mediated sensitization, but the presence of allergen-specific IgE does not by itself establish clinical reactivity. Clinical allergy must be determined from the patient's history and, when appropriate, a supervised challenge; patch testing is used for delayed T-cell-mediated responses.

    Terminology and Testing Modalities

    IgE
    TermIgE
    MeaningImmunoglobulin E
    Clinical roleThe immunoglobulin primarily involved in allergic disease.
    sIgE
    TermsIgE
    MeaningSpecific immunoglobulin E
    Clinical roleAllergen-specific immunoglobulin E used to identify sensitization to particular allergens.
    SPT
    TermSPT
    MeaningSkin prick tests
    Clinical roleTesting used to assess sensitization to allergens.
    BAT
    TermBAT
    MeaningBasophil activation flow cytometry testing
    Testing typeA flow-cytometry method for assessing basophil activation after allergen exposure.
    ALCAT
    TermALCAT
    Expanded nameAntigen Leukocyte Antibody Test
    Coverage statusDoes not meet coverage criteria under this policy.
    ABPA
    TermABPA
    Expanded nameAllergic bronchopulmonary aspergillosis
    Testing contextSPT may be considered when IgE sensitization is part of the disease pathogenesis, although utility is described as controversial.
    Skin prick testing (SPT)
    MethodAllergen is introduced into the skin, generally by percutaneous prick or puncture; intradermal testing may be used when indicated.
    PurposeDetects allergen-specific IgE antibodies and assesses IgE-mediated sensitization.
    InterpretationResults must be interpreted with the medical history, clinical findings, and relevant allergens.
    Specific IgE (sIgE) testing
    Test typeAn in-vitro assay
    MeasurementMeasures IgE antibodies directed against specific allergens.
    Selection principleSelected allergens should reflect the patient's age, history, environment, living conditions, occupation, and activities.
    Oral food challenge (OFC)
    ProcedureA supervised ingestion procedure involving a suspected food or other allergen.
    PurposeAssesses clinical reactivity.
    InterpretationFood allergy evaluation should be individualized, and test results alone should not be considered diagnostic.
    Basophil activation test (BAT)
    Test typeAn in-vitro functional assay
    MeasurementMeasures basophil activation after stimulation with an allergen, including markers such as CD63 or CD203c.
    Clinical contextThe policy describes BAT as a developing or limited-use method requiring appropriate validation and standardization.
    Allergic contact dermatitis (ACD)
    ConditionAllergic contact dermatitis
    Diagnostic standardPatch testing is the gold standard to confirm the diagnosis.
    Clinical presentationIt may involve chronic eczematous or noneczematous dermatitis, including localized eruptions of the hands, face, or eyelids.
    Local allergic rhinitis
    ConditionLocal allergic rhinitis
    Testing patternSymptoms and nasal allergen provocation may be present despite negative skin-prick testing.
    Serum findingSerum-specific IgE may be absent.
    CD-sens
    MeasureCD-sens
    Calculation1/EC50 × 100
    EC50 definitionEC50 is the half-maximal effective concentration.
    Sensitization
    MeaningThe presence of allergen-specific IgE indicates sensitization or risk for allergy.
    Diagnostic limitationSensitization is not equivalent to clinical allergy.
    InterpretationAllergen-specific IgE alone cannot establish the probability or severity of an allergic reaction.
    Serum-specific IgE (sIgE)
    Test typeA blood test measuring allergen-specific IgE antibodies.
    UseMay be used when skin-prick testing cannot be performed.
    Examples of limitationsUse may be appropriate with extensive dermatitis, dermatographism, or inability to discontinue antihistamines.
    Skin-prick testing (SPT)
    MethodA percutaneous test using allergen extracts.
    PurposeAssesses IgE-mediated sensitization.
    Clinical useUseful for several allergic conditions and has diagnostic properties similar to serum-specific IgE.
    Oral food challenge (OFC)
    ProcedureA supervised exposure to a suspected food.
    Evaluation roleUsed as part of individualized food-allergy evaluation.
    Diagnostic roleWhen appropriate, may be used to confirm the diagnosis.